Back

Phototherapy with physically and molecularly produced light for Alzheimer's disease

Kuang, S.; Zhu, B.; Zhang, J.; Yang, F.; Wu, B.; Ding, W.; Sheng, S.; Zhang, C.; Ran, C.

2022-05-12 biochemistry
10.1101/2022.02.10.478818 bioRxiv
Show abstract

Over the past decades, classical drug development approaches for Alzheimers disease have yielded limited success, and this futileness has prompted scientists to seek non-classical approaches. In this report, we demonstrated that, with irradiation of LED light or with molecularly generated light (dubbed as "molecular light") from chemiluminescence probe ADLumin-4, photolabile curcumin analogue CRANAD-147 could change properties, structures (sequences) and neurotoxicity of amyloid beta (A{beta}) species in vitro. We further demonstrated that, with the assistance from molecular chemiluminescence imaging, the combination of CRANAD-147/LED or CRANAD-147/ADLumin-4 (molecular light) could slow down the accumulation of A{beta}s in transgenic 5xFAD mice in vivo. Due to the unlimited capacity of tissue penetration of molecular light in vivo, phototherapy with the combination of photolabile A{beta} ligand and molecular light has great potential as an alternative approach for AD drug discovery.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.